TOURMALINE BIO INC. - COMMON STOCK

18.80

14-March-25 15:45:00

15 minutes delayed

Stocks

+1.76

+10.33%

Today's range

17.53 - 18.82

ISIN

N/A

Source

NASDAQ

Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

01 Feb 2024 07:00:00 By Nasdaq GlobeNewswire
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

29 Jan 2024 15:01:00 By Nasdaq GlobeNewswire
Tourmaline Bio Announces Pricing of Public Offering of Common Stock

25 Jan 2024 06:00:00 By Nasdaq GlobeNewswire
Tourmaline Bio Announces Proposed Public Offering of Common Stock

24 Jan 2024 15:05:48 By Nasdaq GlobeNewswire
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)

08 Jan 2024 06:00:00 By Nasdaq GlobeNewswire
Tourmaline Bio added to the NASDAQ Biotechnology Index

15 Dec 2023 15:00:00 By Nasdaq GlobeNewswire
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board

14 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.